Oncology Clinical Development Expertise

With an estimated 1.9 million cancer diagnoses and more than 600,000 cancer deaths forecasted in the US alone in 2021, it is more important than ever to continue the ongoing push for new, effective cancer treatments. Fortunately, there are more oncology trials in clinical development than ever before. In fact, the number of oncology trials has nearly doubled in the past 10 years. But the complexity of oncology trials has grown as well, making them more challenging to recruit and execute and more difficult to retain patients.

With competition and complexity at an all time high, you need a CRO that understands the unique challenges of oncology trials and the expertise to operationalize your study design successfully. Whether you’re embarking on your Phase I dose-finding study or gearing up for your Pivotal Phase III trial, Aperio will provide the expertise and attention your trial deserves.

Our Experience

Aperio team members have managed and executed more than 140 oncology trials across multiple indications, treatment modalities and phases.

142
Total #
Studies

80%
% of Staff
with Experience

32
Total # of
Indications

We have extensive clinical development expertise in a variety of study designs and specialties, such as:

  • Dose escalation studies
  • Early to late phase trials
  • Operationalizing complex, challenging protocols
  • Cohort management, umbrella, basket studies, adaptive trials
  • Site feasibility
  • Patient recruitment/retention
  • Oncology Focused EDC Programming
  • Data driven approach / analytics
  • Immuno-Oncology
  • Oncolytic virus experience

Our team members are experienced across a wide-range of solid tumor and hematology-oncology indications, including lung, breast, prostate and gynecological cancers, non-Hodgkin’s lymphoma, skin and hematological cancers.

SOLID TUMORINDICATIONS

  • Advanced Solid Tumors
  • Lung
  • Breast
  • Gastrointestinal
  • Prostate
  • Non-Small Cell Lung
  • Skin
  • Pancreatic
  • Colorectal
  • Bladder
  • Head and Neck
  • Renal
  • Gynecologic Cancer
  • Glioblastoma
  • Glioma
  • Thyroid

HEMATOLOGY ONCOLOGY INDICATIONS

  • Chronic Lymphocytic Leukemia (CLL)
  • Hematologic Malignancies
  • Acute Myeloid Leukemia (AML)
  • Leukemia
  • Non-Hodgkin's Lymphoma
  • Lymphoma
  • Acute Lymphocytic Leukemia (ALL)
  • Bone Marrow
  • Myelodysplastic Syndrome (MDS)

MEET THE EXPERT

Need help from an oncology expert?

Aperio’s Chief Operating Officer Suzanne Kincaid has 25+ years’ experience managing phase I-III oncology trials. She has deep expertise in operationalizing a wide range of complex oncology trial designs. Suzanne was the Study Delivery Program Leader of AstraZeneca’s Oncology Phase I Team for the US and Director of Operations at Sarah Cannon’s Phase I Drug Development Unit.

Reach out to Suzanne with questions about your oncology trial needs today.

Contact Us

YOU MAY ALSO BE INTERESTED IN

BLOG

4 Things Every Biotech Look For. Read now. 

VIDEO

Part 1 – Clinical Outsourcing Series. Watch now.